Belotte, Jimmy
Felicetti, Brunella
Baines, Amanda J.
YoussefAgha, Ahmed
Rojas-Espaillat, Luis
Ortiz, Ana Godoy
Provencher, Diane
Vázquez, Raúl Márquez
Cortijo, Lucia González
Zeng, Xing
Funding for this research was provided by:
GSK
Article History
Received: 21 August 2023
Accepted: 26 April 2024
First Online: 4 May 2024
Declarations
:
: The OPAL-C trial is approved by the IRB or IEC at each study site and performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Council for Harmonization.
: Consent for publication is not applicable as there are no personal or clinical details of individual participants presented. Model participant information and consent forms can be requested on demand upon reasonable request.
: Jimmy Belotte is an employee of GSK. Brunella Felicetti is an employee of GSK. Amanda J. Baines is an employee of GSK. Ahmed YoussefAgha is an employee of GSK. Luis Rojas-Espaillat has nothing to disclose. Ana Godoy Ortiz has nothing to disclose. Diane Provencher has nothing to disclose. Raúl Márquez Vázquez reports honoraria from AstraZeneca, GSK, and MSD as well as support for attending meetings from GSK and MSD. Lucia González Cortijo reports consulting fees from GSK and MSD as well as fees for non-CME services received directly from Gilead, GSK, MSD, and Roche. Xing Zeng has nothing to disclose.